Company: LENZ
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001628280-25-016822
Chunk: 49

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-04
Form: S-3
Chunk 49
---
 investment-grade securities, certificates of deposit or government securities.

<div align='center'>S-11</div>

### DIVIDEND POLICY
Other than a special cash dividend paid to our stockholders in connection with the Merger, we have never declared or paid any cash dividends on shares of our common stock. We anticipate that we will retain all of our future earnings to advance the development of expansion of our business, and do not anticipate paying any cash dividends on shares of our common stock in the foreseeable future. Any future determination to declare cash dividends on shares of our common stock will be made at the discretion of our board of directors, subject to applicable law and contractual restrictions and will depend on its financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors may deem relevant.

<div align='center'>S-12</div>

### DILUTION
Our net tangible book value as of December 31, 2024, was approximately $204.1 million, or $7.41 per share. Net tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of December 31, 2024. Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the as adjusted net tangible book value per share of our common stock immediately after giving effect to this offering.

After giving effect to the sale of our common stock in the aggregate amount of $150.0 million in this offering at an assumed offering price of $23.00, the last reported sale price of our common stock on Nasdaq on April 3, 2025, and after deducting commissions and estimated aggregate offering expenses payable by us, our as adjusted net tangible book value as of December 31, 2024, would have been approximately $349.1 million, or $10.25 per share. This represents an immediate increase in net tangible book value of $2.84 per share to existing stockholders and immediate dilution in net tangible book value of $12.75 per share to new investors purchasing our common stock in this offering. The following table illustrates this dilution on a per share basis:

| Assumed public offering price per share                                                                                        |     |   |      |     | $ | 23.00 |
| Net tangible book value per share as of December 31, 2024                                                                      |     | $